ClinicalTrials.gg
CompletedNCT01555164Updated Sep 23, 2014Results posted

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

A Phase 3 interventional study of Ranolazine and Placebo to match ranolazine in Type 2 Diabetes Mellitus, sponsored by Gilead Sciences. Completed at 146 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-09-23.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
442
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ranolazine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Ranolazine · Diabetes Mellitus, Type 2.

Enrollment
3rd of 11
442 · median 47
Started
2012
with 3 others
Phase 3
4 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
9 of 11
Gilead Sciences

Among the 11 studies testing ranolazine in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 4 that started in 2012, is one of 4 in phase 3, and was the 8th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About ranolazine

Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the effect of ranolazine when added to metformin on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current treatment with stable metformin therapy in addition to diet and exercise.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented history of T2DM
  • Metformin therapy at a stable total daily dose ≥ 1500 mg and ≤ 2550 mg in addition to diet and exercise for ≥ 8 weeks prior to Screening
  • (BMI) 25 to 45 kg/m\^2, inclusive, at Screening
  • within specified ranges at Screening and at the end of the Qualifying Period based on current metformin dose
  • C-peptide ≥ 0.8 ng/mL at Screening
  • Fasting serum glucose (FSG) ≥ 130 mg/dL (7.2 mmol/L) and ≤ 240 mg/dL (13.3 mmol/L) at Screening and at the end of the Qualifying Period

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • History of diabetic ketoacidosis, ketosis-prone diabetes, or hyperosmolar hyperglycemic coma
  • History of severe hypoglycemia
  • Any cardiovascular or cerebrovascular event ≤ 3 months prior to Screening
  • History of congestive heart failure
  • interval (QTc) > 500 msec by at Screening, a personal or family history of QTc prolongation, congenital long QT syndrome, or individuals who are receiving drugs that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents, erythromycin, and certain antipsychotics (eg, ziprasidone)
  • Serum creatinine concentration ≥ 1.5 mg/dL for males or ≥ 1.4 mg/dL for females at Screening
  • Active liver disease and/or significant abnormal liver function defined as (AST) > 3 x (ULN) and/or alanine aminotransferase (ALT) > 3 x ULN and/or serum total > 2.0 mg/dL
  • Use of any non-insulin antihyperglycemic therapy (other than metformin) for more than 14 days (consecutive or not) during the 12 weeks (24 weeks for thiazolidinediones) prior to Screening and/or use of any antihyperglycemic therapy other than metformin, at any dose, at any time during the 4 weeks prior to randomization
  • Treatment with chronic insulin within 24 weeks prior to Screening (except for one temporary period of daily insulin injections no longer than 7 days)
  • Treatment with strong or moderate cytochrome P450 3A () inhibitors or P-glycoprotein (P-gp) inhibitors within 14 days prior to randomization
  • Treatment with CYP3A inducers or P-gp inducers within 14 days prior to randomization
  • Treatment with simvastatin or lovastatin at a dose > 20 mg or > 40 mg daily, respectively, within 14 days prior to randomization
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
442 participants (actual)

Study arms

  • Experimental
    Ranolazine+metformin

    Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening). Treatment Period: Participants will receive ranolazine 500 mg + metformin 500 mg + placebo to match metformin twice daily on Days 1 through 7, followed by ranolazine 1000 mg + metformin 500 mg + placebo to match metformin twice daily from Day 8 through Week 24. Participants are required to maintain their diet and exercise regimen.

    Drug: Ranolazine · Drug: Metformin · Drug: Placebo to match metformin · Behavioral: Diet · Behavioral: Exercise

  • Placebo comparator
    Placebo+metformin

    Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening). Treatment Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily through Week 24. Participants are required to maintain their diet and exercise regimen.

    Drug: Placebo to match ranolazine · Drug: Metformin · Behavioral: Diet · Behavioral: Exercise

Interventions

  • Ranolazine tablet(s) administered orally

    Also known as: Ranexa®

  • DrugPlacebo to match ranolazine

    Placebo to match ranolazine for the duration of the study

  • Metformin tablet(s) administered orally once daily

  • DrugPlacebo to match metformin

    Placebo to match metformin for the duration of the study

  • BehavioralDiet

    Participants are instructed to continue the diet regimen prescribed by their physician.

  • BehavioralExercise

    Participants are instructed to continue the exercise regimen prescribed by their physician.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

    The average (mean) change from baseline in HbA1c at Week 24 was analyzed.

    Time frame: Baseline; Week 24

Secondary outcomes

  1. Change From Baseline in Fasting Serum Glucose at Week 24

    The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.

    Time frame: Baseline; Week 24

  2. Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24

    The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed. Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at T=120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations; analyzed based on the randomized treatment regardless of actual treatment received.

    Time frame: Baseline; Week 24

07

Results

Posted Sep 23, 2014

Participant flow

Participants were enrolled (during the Qualifying Period) at a total of 112 study sites in Canada, Europe, Asia, Mexico, South Africa, and the United States. The first participant was screened on 28 June 2012. The last participant observation occurred on 01 October 2013.

Participant flow — Overall Study
MilestonePlacebo+MetforminRanolazine+Metformin
Started222220
Completed182185
Not completed4035
Withdrew: Adverse event57
Withdrew: Hyperglycemia01
Withdrew: Investigator's discretion22
Withdrew: Lost to follow-up43
Withdrew: Protocol violation95
Withdrew: Subject non-compliance146
Withdrew: Subject withdrew consent611

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

The average (mean) change from baseline in HbA1c at Week 24 was analyzed.

Time frame:
Baseline; Week 24
Reported as:
Mean · percent of HbA1c in blood
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
percent of HbA1c in bloodPlacebo+MetforminRanolazine+Metformin
HbA1c at Week 247.86 ± 1.0037.72 ± 1.069
Change from baseline in HbA1c at Week 24-0.20 ± 0.949-0.37 ± 0.916
Statistical analysis
  • Placebo+Metformin vs Ranolazine+Metformin · Mixed Effects Model Analysis · p = 0.306 (P-value from a mixed-effect model including terms for baseline HbA1c value, treatment group, visit week, and treatment by visit week interaction. Unstructured covariance matrix was used.) · Difference in least squares mean (lsm): -0.11 · 95% CI -0.31 to 0.10The estimation (LSM) is of the placebo-corrected change from baseline.
SecondaryChange From Baseline in Fasting Serum Glucose at Week 24

The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.

Time frame:
Baseline; Week 24
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Serum Glucose at Week 24
mg/dLPlacebo+MetforminRanolazine+Metformin
Change From Baseline in Fasting Serum Glucose at Week 24-3 ± 44.73 ± 42.5
SecondaryChange From Baseline in 2-hour Postprandial Serum Glucose at Week 24

The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed. Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at T=120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations; analyzed based on the randomized treatment regardless of actual treatment received.

Time frame:
Baseline; Week 24
Reported as:
Mean · mg/dL
Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24
mg/dLPlacebo+MetforminRanolazine+Metformin
Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24-4 ± 54.07 ± 58.2

Adverse events

Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo+Metformin—2/222 (0.9%)14/222 (6.3%)
Ranolazine+Metformin—3/220 (1.4%)18/220 (8.2%)
Most frequent serious events
Most frequent serious events
EventPlacebo+MetforminRanolazine+Metformin
Impaired gastric emptyingGastrointestinal disorders0/2221/220
VomitingGastrointestinal disorders0/2221/220
Lower limb fractureInjury, poisoning and procedural complications0/2221/220
Metabolic acidosisMetabolism and nutrition disorders0/2221/220
Spinal osteoarthritisMusculoskeletal and connective tissue disorders1/2221/220
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/2221/220
Coronary artery diseaseCardiac disorders1/2220/220
Myocardial infarctionCardiac disorders1/2220/220
Most frequent other events
Most frequent other events
EventPlacebo+MetforminRanolazine+Metformin
HyperglycaemiaMetabolism and nutrition disorders14/22218/220

Baseline characteristics

Safety Analysis Set: randomized participants who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(years)Placebo+MetforminRanolazine+MetforminTotal
Mean56 ± 8.956 ± 9.356 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo+MetforminRanolazine+MetforminTotal
Female98121219
Male12499223
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo+MetforminRanolazine+MetforminTotal
Hispanic or Latino533790
Not Hispanic or Latino166181347
Unknown or Not Reported325
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo+MetforminRanolazine+MetforminTotal
American Indian or Alaska Native202
Asian5254106
Black or African American81119
White160153313
Other022
Region of Enrollment
Region of Enrollment(participants)Placebo+MetforminRanolazine+MetforminTotal
United States8267149
Hungary8816
Czech Republic011
Mexico6410
Canada134
Poland055
Ukraine352964
South Africa7411
Israel213
Russian Federation374986
India444993
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Placebo+MetforminRanolazine+MetforminTotal
Mean31.2 ± 4.4631.6 ± 4.9531.4 ± 4.71
Estimated glomerular filtration rate (eGFR)
Estimated glomerular filtration rate (eGFR)(mL/min/1.73m^2)Placebo+MetforminRanolazine+MetforminTotal
Mean90.8 ± 20.0189.9 ± 21.8290.4 ± 20.91
Glycosylated hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c)(percent HbA1c in blood)Placebo+MetforminRanolazine+MetforminTotal
Mean8.09 ± 0.7298.10 ± 0.6928.09 ± 0.710

2 further baseline measures are reported on the registry.

08

Study locations

146 sites
  • Fundamental Research LLC
    Gulf Shores, Alabama 36542, United States
  • KLR Business Group DBA Arkansas Clinical Research
    Little Rock, Alaska 72205, United States
  • Radiant Research, Inc.
    Chandler, Arizona 85224, United States
  • Central Phoenix Medical Clinic
    Phoenix, Arizona 85020, United States
  • Clinical Research Advantage
    Tempe, Arizona 85282, United States
  • Desert Sun Clinical Research, LLC
    Tucson, Arizona 85710, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Ritchken and First MD's
    San Diego, California 92117, United States
  • Clearview Medical Research, LLC
    Santa Clarita, California 91350, United States
  • Metabolic Institute of America
    Tarzana, California 91356, United States
  • University Clinical Investigators
    Tustin, California 92780, United States
  • Infosphere Clinical Research
    West Hills, California 91307, United States
  • Colorado Springs Health Partners
    Colorado Springs, Colorado 80906, United States
  • Boca Raton Clinical Research Associates, Inc.
    Boca Raton, Florida 33432, United States
  • MD Clinical Institute
    Hallandale Beach, Florida 33009, United States
  • A G A Clinical Trials
    Hialeah, Florida 33012, United States
  • Baptist Diabetes Associates
    Miami, Florida 33156, United States
  • Florida Institute for Clinical Research LLC
    Orlando, Florida 32822, United States
  • Medical Research Group of Central Florida
    Sanford, Florida 32771, United States
  • Synergy Therapeutic Partners
    Atlanta, Georgia 30312, United States
  • Perimeter Institute for Clinical Research
    Atlanta, Georgia 30338, United States
  • Columbus Research Foundation
    Columbus, Georgia 31904, United States
  • Advanced Clinical Research
    Boise, Idaho 83642, United States
  • Choose To Lose
    Eagle, Idaho 83616, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Alexandria Cardiology Clinic
    Alexandria, Louisiana 71301, United States
  • Covington Medical Care
    Mandeville, Louisiana 70471, United States
  • Clinical Trials Management, LLC
    Metairie, Louisiana 70006, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Bellevue Family Practice
    Bellevue, Nebraska 68005, United States
  • Clinical Research Advantage
    Henderson, Nevada 89052, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87131-0001, United States
  • PhysiqueMed Clinical Trials
    Greensboro, North Carolina 27405, United States
  • Clinical Trials of America Inc
    Hickory, North Carolina 28601, United States
  • University Medical Associates
    Huntersville, North Carolina 28078, United States
  • Northstate Clinical Research
    Lenoir, North Carolina 28645, United States
  • Carolina Research Center
    Shelby, North Carolina 28150, United States
  • Lillestol Research
    Fargo, North Dakota 58103, United States
  • Rapid Medical Research, Inc
    Cleveland, Ohio 44122, United States
  • Columbus Clinical Research Inc.
    Columbus, Ohio 43213, United States
  • Hometown Urgent Care and Research
    Dayton, Ohio 45432, United States
  • Blair Medical Associates Inc.
    Altoona, Pennsylvania 16602, United States
  • Safe Harbor Clinical Research
    East Providence, Rhode Island 02914, United States
  • Pharmacorp Clinical Trials, Inc.
    Charleston, South Carolina 29412, United States
  • DeGarmo Institute of Medical Research
    Greer, South Carolina 29651, United States
  • Holston Medical Group, P.C.
    Bristol, Tennessee 37620, United States
  • New Phase Research & Development
    Knoxville, Tennessee 37923, United States
  • Corpus Christi, Texas 78414, United States
  • Dallas Diabetes and Endocrine Center
    Dallas, Texas 75230, United States
  • West Houston Clinical Research
    Houston, Texas 77055, United States
  • Juno Research, LLC
    Houston, Texas 77074, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • Juno Research, LLC
    Katy, Texas 77450, United States
  • Northeast Clinical Research of San Antonio, LLC
    Schertz, Texas 78154, United States
  • Sugarland, Texas 77479, United States
  • Progressive Clinical Research, LLC
    Bountiful, Utah 84010, United States
  • Highland Clinical Research
    Salt Lake City, Utah 84124, United States
  • Burke Internal Medicine, Inc.
    Burke, Virginia 22015, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • The Medical Arts Health Research Group
    Kelowna, British Columbia V1Y 3G8, Canada
  • Diabetes Research Clinic
    Vancouver, British Columbia V5Z 1L8, Canada
  • Joanne F. Liutkus Medicine Professional Corporation
    Cambridge, Ontario N1R7L6, Canada
  • Source Unique Research
    Hawkesbury, Ontario K6A 1A1, Canada
  • Nemocnice s poliklinikou Havirov
    Havirov, Moravskoslezsky kraj 736-01, Czech Republic
  • Restrial s.r.o.
    Praha 8, Praha 18100, Czech Republic
  • Synexus Hungary Ltd
    Budapest, 1036, Hungary
  • Selye János Kórház és Rendel?intézet, Belgyógyászati Szakrendelés
    Komárom, 2900, Hungary
  • Kanizsai Dorottya Hospital
    Nagykanizsa, 8800, Hungary
  • Medifarma 98
    Nyíregyháza, 4400, Hungary
  • Borbanya Praxis Kft., Outpatient Clinic
    Nyíregyháza, 4405, Hungary
  • Diabetomics India
    Hyderabad, Andhra Pradesh 500034, India
  • DHL Research Centre, 2nd Floor
    Ahmadabad, Gujarat 380015, India
  • Dia Care- A Complete Diabetes Care Center
    Ahmadabad, Gujarat 380015, India
  • Baroda Medical College and SSG Hospital
    Vadodara, Gujarat 390001, India
  • Banker's Heart Institute
    Vadodara, Gujarat 390015, India
  • Endocrinology & Diabetes Research Centre
    Bangalore, Karnataka 560003, India
  • Manipal Hospital
    Bangalore, Karnataka 560017, India
  • Endocrinology Diabetes Centre
    Bangalore, Karnataka 560038, India
  • Bangalore Diabetes Hospital
    Bangalore, Karnataka 560043, India
  • The Bangalore Diabetes Hospital
    Bangalore, Karnataka 560052, India
  • Jnana Sanjeevani Medical Center
    Bangalore, Karnataka 560078, India
  • Vinaya Hospital and Research Centre
    Mangalore, Karnataka 575003, India
  • Seth G. S. Medical College and KEM Hospital
    Mumbai, Maharashtra 400012, India
  • Institue of Clinical Endocrinology (I.C.E) and Diabetes Care Unit (D.C.U),
    Nagpur, Maharashtra 440010, India
  • Getwell Hospital and Research Institute
    Nagpur, Maharashtra 440012, India
  • Diabetes Care and Research Centre
    Pune, Maharashtra 411011, India
  • KEM Hospital Research Center
    Pune, Maharashtra 411011, India
  • Fortis City Centre
    Chandigarh, Punjab 160017, India
  • Diabetes and Heart Centre
    Ludhiana, Punjab 141008, India
  • Swamy Diabetes Centre
    Chennai, Tamilnadu 600028, India
  • Madras Diabetes Research Foundation
    Chennai, Tamilnadu 600086, India
  • Kovai Diabetes Speciality Centre & Hospital
    Coimbatore, Tamilnadu 641009, India
  • Soroka University Medical Center
    Beer Sheva, 84101, Israel
  • Edith Wolfson Medical Center
    Holon, 58100, Israel
  • Ziv Medical Center Safed-Israel
    Safed, 13100, Israel
  • Instituto Jalisciense de Investigación en Diabetes y Obesidad
    Guadalajara, Jalisco 44600, Mexico
  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska Sp. Komandytowo - Akcyjna
    Lodz, Lodzkie 90242, Poland
  • LANDA - Specjalistyczne Gabinety Lekarskie
    Krakow, Malopolskie 30-015, Poland
  • Niepubliczy Zaklad Opieki Zdrowotnej (NZOZ) Specjalistyczny Osrodek Internistyczno - Diabetologiczny
    Bialystok, 15-435, Poland

Showing the first 100 of 146 sites across 11 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Sep 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year after primary completion. A results delay was requested in Jan 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2012
First posted
Mar 15, 2012
Start
Jun 2012
Primary completionActual
Sep 2013
CompletionActual
Oct 2013
Results delay requested
Jan 17, 2014
Results first posted
Sep 23, 2014
Last update
Sep 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01555164
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 15, 2012
Start date
Jun 2012
Primary completion
Sep 2013
Completion
Oct 2013
Results posted
Sep 23, 2014
Last update
Sep 23, 2014

Study contacts

Patrick Yue, MD
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion